

***Fiscal Year 2018 Department of Defense Amyotrophic Lateral Sclerosis Program  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<b>Therapeutic Development Award</b> Go to: <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> W81XWH-18-ALSRP-TDA	Independent investigators at all levels	<ul style="list-style-type: none"> <li><b>Pre-application is required; full application submission is by invitation only.</b></li> <li>Supports post-discovery, preclinical development of therapeutics for ALS</li> <li>Preliminary data, including identity and purity of an identified bioactive compound(s), are required</li> <li>Types of efforts that will be supported include: <ul style="list-style-type: none"> <li>Confirmation of candidate therapeutics obtained from screening or by other means</li> <li>Validation of lead pharmacological agents up to IND submission</li> <li>Optimization of potency and pharmacology, studies of formulation, stability, and production methods based on Good Manufacturing Practices</li> <li>Investigational New Drug (IND)-enabling studies</li> </ul> </li> <li>Collaboration with industry is encouraged</li> <li>Clinical trials are not allowed</li> <li>Does not support screening or development of screens or models</li> </ul> <p><b>New! The following option, with additional funding for qualified applications, is being offered:</b></p> <ul style="list-style-type: none"> <li>Therapeutically Relevant Marker Option supports development of markers that will improve the drug development process in parallel with the main therapeutic advancement effort.</li> <li>Applicants must submit a Therapeutically Relevant Marker Statement that clearly describes how the marker is quantifiable and has potential to improve the efficacy of the therapy development process.</li> <li>Application to this option is not a requirement for TDA submission</li> </ul>	<ul style="list-style-type: none"> <li>Maximum period of performance is <b>2</b> years.</li> <li>Maximum funding of <b>\$1,000,000</b> for direct costs for the standard award.</li> <li>Maximum funding of <b>\$1,250,000</b> for direct costs for submissions under the Therapeutically Relevant Marker Option</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<p><b>Pre-Application (Preproposal):</b>  June 22, 2018  5:00 p.m. Eastern time</p> <p>Preproposal is required; application submission is by invitation only.</p> <p><b>Application:</b>  October 11, 2018  11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
		<ul style="list-style-type: none"> <li>A TDA application requesting the higher level of funding that does meet the specified criteria may be funded at the lower level</li> </ul>		
<b>Therapeutic Idea Award</b> Go to: <ul style="list-style-type: none"> <li>Program Announcement</li> <li>General Application Instructions</li> </ul> <b>Grants.gov Funding Opportunity Number:</b> W81XWH-18-ALSRP-TIA	Independent investigators at all levels	<ul style="list-style-type: none"> <li>Pre-application is required; full application submission is by invitation only.</li> <li>Supports new ideas aimed at ALS drug or treatment discovery that are still in the early stages of development</li> <li>Preliminary data are not required</li> <li>Types of efforts that will be supported include: <ul style="list-style-type: none"> <li>Exploitation of pathways known to be relevant to ALS for the purpose of improving treatment and/or advancing a novel treatment modality</li> <li>Development, modification, and use of novel high-throughput screens and model systems to <b>define or assess</b> lead compounds</li> <li>Projects that focus primarily on investigating the pathophysiology of ALS are outside of the scope of this announcement Characterization of mechanisms for the purpose of identifying new targets is outside of the scope of this announcement</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Maximum period of performance is <b>2</b> years.</li> <li>Maximum funding of <b>\$500,000</b> for direct costs.</li> <li>Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul>	<b>Pre-Application (Preproposal):</b> June 22, 2018 5:00 p.m. Eastern time  Preproposal is required; Application submission is by invitation only.  <b>Application:</b> October 11, 2018 11:59 p.m. Eastern Time

**Commented [CGMCUMC(1)]:** Suggest replacing with "discover or evaluate"